The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 13, 2018
Filed:
Mar. 19, 2014
Applicant:
Novartis Ag, Basel, CH;
Inventors:
Giordano Caponigro, Cambridge, MA (US);
Darrin Stuart, Emeryville, CA (US);
Laure De Parseval, Basel, CH;
Assignee:
NOVARTIS AG, Basel, CH;
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/506 (2006.01); A61K 45/06 (2006.01); A61K 31/4184 (2006.01); A61K 31/4439 (2006.01); A61K 31/4745 (2006.01); A61K 31/496 (2006.01); A61K 31/519 (2006.01); A61K 31/53 (2006.01); A61K 31/5377 (2006.01); A61K 9/00 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01); C12Q 1/68 (2018.01);
U.S. Cl.
CPC ...
A61K 31/506 (2013.01); A61K 9/0053 (2013.01); A61K 9/20 (2013.01); A61K 9/48 (2013.01); A61K 31/4184 (2013.01); A61K 31/4439 (2013.01); A61K 31/4745 (2013.01); A61K 31/496 (2013.01); A61K 31/519 (2013.01); A61K 31/53 (2013.01); A61K 31/5377 (2013.01); A61K 45/06 (2013.01); C12Q 1/6886 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/156 (2013.01);
Abstract
Reversing resistance to a B-Raf inhibitor for the treatment of a proliferative disease by obtaining a tumor sample from the patient and testing it for genetic alterations in a panel of genes comprising BRAF, CRAF, CCND1, CDK4, HER2, IGF-1R, cMET, FGFR1, FGFR2, FGFR3 EGFR, MAP2K1, MAP2K2, NRAS, KRAS HRAS, PTEN, PIK3CA, and P16 and administering a drug combination therapy comprising the B-Raf inhibitor and a second inhibitor which overcomes resistance to the B-Raf inhibitor, which second inhibitor is selected based on genetic alterations discovered in the tumor sample.